Investment Summary |
|
|---|---|
| Date | 2021-01-15 |
| Target | Farmalisto |
| Sector | Life Science |
| Investor(s) | HBM Partners |
| Deal Type | Growth Capital |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 52 of 65 |
| Sector: Life Science M&A | 45 of 56 |
| Type: Growth Capital M&A Deals | 5 of 7 |
| Country: Colombia M&A | 1 of 1 |
| Year: 2021 M&A | 5 of 15 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-13 |
IO Biotech
Copenhagen, Denmark IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech's pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2014 and is based in Copenhagen, Denmark. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-01 |
Viela Bio
Gaithersburg, Maryland, United States Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Viela Bio was founded in 2018 and is based in Gaithersburg, United States. |
Sell | $3.1B |
